|Chemical and physical data|
|Molar mass||3339.75 g/mol g·mol−1|
|(what is this?)|
Two phase II trials reported it was effective and well tolerated.
Of the eight planned phase III clinical trials of weekly taspoglutide (four against exenatide, sitagliptin, insulin glargine, and pioglitazone), at least five were active in 2009. Preliminary results in early 2010 were favourable. (At least one of the eight planned phase III trials had not started recruiting by end 2009.)
Taspoglutide is the peptide with the sequence H2N-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH2.
In other words, it is the 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide derivative of the amino acid sequence 7–36 of human glucagon-like peptide I.
- "Ipsen: Roche Moves Investigational Diabetes Drug, Taspoglutide, into Phase III Clinical Trials". Business Wire. June 2008.
- "Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials". June 2008.
- Baggio; et al. (2008). "Glucagon-like Peptide-1 Analogs Other Than Exenatide".
- "Ipsen's Partner Roche Announces That Taspoglutide Meets Its Primary Endpoint In The First Phase III Clinical Trial". October 2009.
- "Roche Reports Positive Data from Five Phase III Trials of Type 2 Diabetes Therapy". February 2010.
- "A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy". Archived from the original on 21 July 2011. Retrieved 12 February 2010.
- "Roche Halts Trials of Taspoglutide".
- "Experimental Diabetes Drug Taspoglutide Late-Stage Trials Suspended".
- Clinical studies of taspoglutide
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|